









Markets
/
Stocks
/
nasdaq-nrxs
/

Neuraxis Inc

NRXS

6.610USD

-0.290-4.20%

Close 03/30, 16:00（ET）Quotes delayed by 15 min

46.21MMarket Cap

LossP/E TTM



Neuraxis Inc

6.610

-0.290-4.20%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Neuraxis Inc

Currency: USD Updated: 2026-03-27

Key Insights

Neuraxis Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 92 out of 208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 8.50.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and strong technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Neuraxis Inc's Score

Industry at a Glance

Industry Ranking

92 / 208

Overall Ranking

222 / 4542

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Neuraxis Inc Highlights

StrengthsRisks

Neuraxis, Inc. is a medical technology company. The Company is focused on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults. It focuses on advancing science and leveraging evidence-based medicine to drive the adoption of its IB-Stim therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is a food and drug administration (FDA) cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. The Company’s second product, the Rectal Expulsion Device (RED), is indicated to evaluate the neuromuscular function of a patient’s ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge defecating at lower volumes of distension.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 45.09% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 3.57M.

Undervalued

The company’s latest PE is -7.28, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 2.04M shares, decreasing 10.15% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 145.56K shares of this stock.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

8.500

Target Price

0.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Neuraxis Inc is 5.87, ranking 183 out of 208 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 968.13K, representing a year-over-year increase of 27.19%, while its net profit experienced a year-over-year increase of 14.73%.

Score

Industry at a Glance

Previous score

5.87

Change



Financials

7.94

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.12

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.84

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.37

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.08

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Neuraxis Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Neuraxis Inc is 7.60, ranking 73 out of 208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -7.28, which is -100.00% below the recent high of 0.00 and -15.63% above the recent low of -8.41.

Score

Industry at a Glance

Previous score

7.60

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 92/208

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Neuraxis Inc is 8.00, ranking 61 out of 208 in the Healthcare Equipment & Supplies industry.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

8.500

Target Price

0.00%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

115

Total

Median

Average

Company name

Ratings

Analysts

Neuraxis Inc

NRXS

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Dexcom Inc

DXCM

Zimmer Biomet Holdings Inc

ZBH

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Neuraxis Inc is 8.88, ranking 12 out of 208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 8.08 and the support level at 5.61, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.97

Change

-0.09

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.165

Neutral

RSI(14)

52.640

Neutral

STOCH(KDJ)(9,3,3)

40.848

Sell

ATR(14)

0.687

High Vlolatility

CCI(14)

-83.175

Neutral

Williams %R

70.466

Sell

TRIX(12,20)

1.331

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

7.014

Sell

MA10

7.136

Sell

MA20

6.678

Sell

MA50

5.594

Buy

MA100

4.414

Buy

MA200

3.551

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Neuraxis Inc is 3.00, ranking 135 out of 208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 19.16%, representing a quarter-over-quarter increase of 18.71%. The largest institutional shareholder is The Vanguard, holding a total of 145.56K shares, representing 1.30% of shares outstanding, with 235.51% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Hannasch (Brian)

1.13M

+61.42%

Bigger Capital Funds, LP

763.98K

+30.82%

Brown (Christopher Robin)

792.84K

AIGH Capital Management, LLC.

297.44K

Money Concepts Capital Corp

33.40K

District 2 Capital LP

151.71K

+43.72%

The Vanguard Group, Inc.

Star Investors

71.63K

+156.00%

Parsons Capital Management, Inc.

116.73K

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Neuraxis Inc is 1.86, ranking 173 out of 208 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.